

# Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Naval Daver, Deborah Thomas, Farhad Ravandi, Jorge Cortes, Rebecca Garris, Elias Jabbour, Guillermo Garcia-Manero, Gautam Borthakur, Tapan Kadia, Michael Rytting, Marina Konopleva, Hagop Kantarjian, and Susan O'Brien

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

---


©2015 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2014.118588

Manuscript received on October 7, 2014. Manuscript accepted on February 2, 2015.

Correspondence: [sobrien@mdanderson.org](mailto:sobrien@mdanderson.org)

# Hyper-CVAD + Imatinib. Design

## Intensive phase







## Maintenance phase



← 24 months →

## Risk-adapted intrathecal CNS prophylaxis

- |  |                |   |                          |
|--|----------------|---|--------------------------|
|  | Hyper-CVAD     |  | Imatinib daily dose      |
|  | MTX-cytarabine |  | Vincristine + prednisone |